Overview

A Study Assessing KB803 Compared to Matching Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa

Status:
RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
KB803-EYE-01 is a Phase 3 double-blind, intra-patient crossover study, to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
Phase:
PHASE3
Details
Lead Sponsor:
Krystal Biotech, Inc.